BriaCell Therapeutics’ (BCTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of BriaCell Therapeutics (NASDAQ:BCTX) in a research report report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $32.00 target price on the stock.

BriaCell Therapeutics Trading Up 11.0 %

BriaCell Therapeutics stock opened at $6.03 on Tuesday. BriaCell Therapeutics has a 12 month low of $3.00 and a 12 month high of $36.60. The business’s fifty day simple moving average is $4.10 and its two-hundred day simple moving average is $7.66. The company has a market capitalization of $22.37 million, a price-to-earnings ratio of -0.45 and a beta of 1.34.

BriaCell Therapeutics (NASDAQ:BCTX) last issued its earnings results on Monday, March 17th. The company reported ($2.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.94) by ($0.39). On average, equities research analysts predict that BriaCell Therapeutics will post -2.45 EPS for the current year.

Hedge Funds Weigh In On BriaCell Therapeutics

Hedge funds have recently bought and sold shares of the business. Vontobel Holding Ltd. grew its position in BriaCell Therapeutics by 37.5% in the 4th quarter. Vontobel Holding Ltd. now owns 110,000 shares of the company’s stock worth $62,000 after purchasing an additional 30,000 shares during the period. Virtu Financial LLC purchased a new position in shares of BriaCell Therapeutics in the fourth quarter worth approximately $27,000. Finally, Cantor Fitzgerald L. P. bought a new position in BriaCell Therapeutics in the fourth quarter worth approximately $32,000. Hedge funds and other institutional investors own 15.42% of the company’s stock.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.